DNAPrint Genomics (OTCMKTS:DNAG – Get Rating) and SomaLogic (NASDAQ:SLGC – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, analyst recommendations and earnings.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for DNAPrint Genomics and SomaLogic, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| DNAPrint Genomics | 0 | 0 | 0 | 0 | N/A |
| SomaLogic | 0 | 0 | 5 | 0 | 3.00 |
SomaLogic has a consensus price target of $8.50, suggesting a potential upside of 168.99%.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| DNAPrint Genomics | N/A | N/A | N/A | N/A | N/A |
| SomaLogic | $97.67 million | 6.08 | -$109.16 million | ($0.59) | -5.36 |
DNAPrint Genomics has higher earnings, but lower revenue than SomaLogic.
Risk & Volatility
DNAPrint Genomics has a beta of -0.55, meaning that its stock price is 155% less volatile than the S&P 500. Comparatively, SomaLogic has a beta of 1.88, meaning that its stock price is 88% more volatile than the S&P 500.
Institutional and Insider Ownership
66.8% of SomaLogic shares are owned by institutional investors. 12.9% of SomaLogic shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares DNAPrint Genomics and SomaLogic’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| DNAPrint Genomics | N/A | N/A | N/A |
| SomaLogic | -111.77% | -22.12% | -19.33% |
Summary
SomaLogic beats DNAPrint Genomics on 5 of the 8 factors compared between the two stocks.
About DNAPrint Genomics
DNAPrint Genomics, Inc. engages in the research and development of genomics-based products and services for biomedical and forensics. The company was founded by Tony N. Frudakis on January 3, 1983 and is headquartered in Sarasota, FL.
About SomaLogic
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. Its SomaScan's biomarker discoveries help in diagnostic applications in various areas of diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal research use only and laboratory-developed tests. It serves research and clinical customers with a focus on pharmaceutical and biotechnology companies, and academic research institutions, as well as facilitates drug development, analysis of clinical trials, and new human biology insights by assessing protein-protein and protein-gene networks. The company was incorporated in 1999 and is headquartered in Boulder, Colorado.
Receive News & Ratings for DNAPrint Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DNAPrint Genomics and related companies with MarketBeat.com's FREE daily email newsletter.
